GKOS
Glaukos Corp
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Glaukos Corp
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
No other changes.
No other changes.
Last report4 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
No thesis.
Largest filed tie
0
filed ties
Annual filing, covered
10-K parsed · Feb 23 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 23 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
+33.65%
vs ±14.8% implied · ×2.27
shaded = implied · ▲▼ = realized
Glaukos Corp
233.10
−5.51 · −2.31%
post 234.73 +0.70%
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $1.3B | 15.46% | +4.95% |
| Jupiter Topco | $679.6M | 7.88% | — |
| Vanguard Portfolioindex-like | $464.3M | 5.38% | +3.54% |
| Primecap | $425.0M | 4.93% | −9.79% |
| Vanguardindex-like | $356.5M | 4.13% | +1.69% |
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $1.3B | 15.46% | +4.95% |
| Jupiter Topco | $679.6M | 7.88% | — |
| Vanguard Portfolioindex-like | $464.3M | 5.38% | +3.54% |
| Primecap | $425.0M | 4.93% | −9.79% |
| Vanguardindex-like | $356.5M | 4.13% | +1.69% |
Tall tick = annual report · Source: EDGAR
Same SIC code · 6
Same SEC industry code: Stryker Corp, 3M Co, Boston Scientific Corp and 3 more; of Glaukos Corp's 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: Stryker Corp, 3M Co, Boston Scientific Corp and 3 more; of Glaukos Corp's 6 closest co-movers, none share that code.
Bull1
Bear2
Expected move
Inputsspot 233.04exp Jan 15ATM strike 230ATM straddle 38.80IV 47%